- Conditions
- Depression
- Interventions
- Placebo, RO4917523
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 9
- States / cities
- Oceanside, California • San Diego, California • New Haven, Connecticut + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 261
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder, Depressive Symptoms
- Interventions
- Medi-TBS
- Combination Product
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Major Depressive Disorder
- Interventions
- tranylcypromine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment Resistant Depression
- Interventions
- Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Soterix Medical
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bipolar Disorder, Treatment Resistant Depression
- Interventions
- Evidence Based Quality Improvement
- Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Eudora, Arkansas • Huntsville, Arkansas • Marianna, Arkansas + 3 more
- Conditions
- Treatment Resistant Depression
- Interventions
- FEAST, FEAST RP
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 22 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder
- Interventions
- AXS-05 (dextromethorphan-bupropion)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Interventions
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Accelerated intermittent theta-burst treatment
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Treatment Resistant Depression, Substance Use Disorders
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Treatment Resistant Depression
- Interventions
- Prefrontal Cortical Stimulation (PCS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Major Depressive Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Treatment Resistant Major Depression
- Interventions
- Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Major Depressive Disorder
- Interventions
- GLYX-13
- Drug
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Treatment Resistant Depression
- Interventions
- Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Vagus Nerve Stimulation (VNS)
- Device
- Lead sponsor
- LivaNova
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more
- Conditions
- Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
- Interventions
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Device
- Lead sponsor
- Nader Pouratian
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Mark Niciu
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
- Interventions
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Major Depressive Disorder
- Interventions
- 5-hydroxytryptophan and Creatine, Placebo control
- Drug · Other
- Lead sponsor
- Brent Michael Kious, MD, PhD
- Other
- Eligibility
- 25 Years to 40 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Eric Lenze
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • St Louis, Missouri
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALKS 5461, ALKS 5461 Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 27 more